BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lechpammer M, Rao R, Shah S, Mirheydari M, Bhattacharya D, Koehler A, Toukam DK, Haworth KJ, Pomeranz Krummel D, Sengupta S. Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers. Cancers (Basel) 2022;14:1627. [PMID: 35406398 DOI: 10.3390/cancers14071627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li S, Peng Y, Ma W, Wang Y, Li W. Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. Cancer Innovation 2023. [DOI: 10.1002/cai2.59] [Reference Citation Analysis]
2 Lu H, Zhou L, Zhang B, Xie Y, Yang H, Wang Z. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.939776] [Reference Citation Analysis]
3 Sun H, Li X, Yang J, Lyu Y, Han P, Zheng J. A Novel Cuprotosis-Related lncRNA Signature Predicts Survival Outcomes in Patients with Glioblastoma. Intelligent Computing Theories and Application 2022. [DOI: 10.1007/978-3-031-13829-4_48] [Reference Citation Analysis]